Ansofaxine

DB15052InvestigationalSmall molecule

Ansofaxine is under investigation in clinical trial NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005).

Mechanism: Pharmacologically active on Sodium-dependent noradrenaline transporter, Sodium-dependent dopamine transporter, and Sodium-dependent serotonin transporter
Curator reviewed
Formula / weight: C₂₄H₃₁NO₃ · 381.516 g/mol (avg)
Also known as: Toludesvenlafaxine
Code names: LY03005

Resolves to

Compound

UNIIA7CGH459FNCAS916918-80-4

Structure

InChIKeyQKYBZJLEMOZFFU-UHFFFAOYSA-NSMILESCN(C)CC(C1=CC=C(OC(=O)C2=CC=C(C)C=C2)C=C1)C1(O)CCCCC1

Targets

P23975SLC6A2Q01959SLC6A3P31645SLC6A4

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ansofaxine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account